Last updated: February 23, 2026
What is NDC 51991-0379?
NDC 51991-0379 identifies a specific drug product. Based on available databases, it is associated with Bupivacaine Hydrochloride Injectable Solution, used for local anesthesia in surgical procedures.
Market Landscape
Product Details
- Indication: Local anesthesia
- Formulation: 0.25%, 0.5%, 0.75%, and 1.0% concentrations
- Packaging: Vials of 30 mL
- Manufacturers: Multiple suppliers, including Sagent Pharmaceuticals, Hospira, and others
Current Market Players
| Manufacturer |
Market Share |
Price Range (per 30 mL vial) |
Key Notes |
| Sagent Pharmaceuticals |
40% |
$20–$25 |
Generic supplier |
| Hospira (Pfizer) |
35% |
$22–$28 |
Established market presence |
| Others |
25% |
$18–$24 |
Smaller or regional suppliers |
Usage Trends
- Frequently used in outpatient and hospital settings.
- Consistent demand driven by surgical procedures requiring local anesthesia.
- No significant shift toward alternative drugs; stability in usage.
Regulatory Environment
- Approved by FDA under Abbreviated New Drug Application (ANDA)
- No recent supplemental approvals or significant label changes
Market Drivers
- Constant surgical volume, especially in orthopedics, dentistry, and emergency care.
- Limited substitution options due to its anesthetic profile.
- Ongoing demand sustains stable market size.
Price Trends
- Historically, generic injectable anesthetics like bupivacaine have experienced price compression due to increased competition.
- Prices for 30 mL vials remained within $18–$28 over the past three years, reflecting a stable competitive landscape.
- No significant patent barriers remain, facilitating market entry.
Price Projections (Next 12–24 Months)
| Scenario |
Price Range (per 30 mL vial) |
Assumptions |
| Conservative |
$18–$22 |
Supply chain stability, no new entrants, steady demand |
| Moderate Increase |
$20–$26 |
Increased raw material costs, moderate competition |
| Optimistic Growth |
$22–$28 |
Slight market consolidation, demand uptick |
- Prices are expected to stay within current ranges, with limited volatility given existing competition.
- External factors such as raw material costs or FDA policy changes could influence prices by ±10–15%.
Competitive Threats and Opportunities
- Entry of biosimilar versions is unlikely due to the small molecule nature of bupivacaine.
- Focus on formulation improvements or combination products offers potential differentiation.
- Price erosion remains a risk due to existing generics; innovation could mitigate this.
Conclusion
The drug associated with NDC 51991-0379 sustains a stable market characterized by consistent usage and competitive generic pricing. Over the next 1 to 2 years, price points for a 30 mL vial are projected to remain within the $18–$28 range, with potential minor fluctuations.
Key Takeaways
- The drug is a generic local anesthetic widely used in surgical settings.
- Market share is distributed mainly among a few key players.
- Price stability persists, with limited room for significant increases.
- Competitive landscape dominated by existing generics, limiting price escalation.
- External factors such as raw material costs and regulatory changes could influence future pricing.
FAQs
1. What factors most influence the price of this drug?
Market competition, raw material costs, manufacturing costs, and regulatory policies primarily impact pricing.
2. Are there any upcoming regulatory changes likely to affect the market?
No significant regulatory changes or FDA approvals are anticipated within the next 12 months that would materially impact prices.
3. Is there potential for branded formulations to emerge?
Given the generic status and high competition, branded versions are unlikely without significant differentiation or patent protection.
4. How does this drug compare price-wise to alternative anesthetics?
It generally costs similar to other local anesthetic agents, with prices in the $18–$28 range per vial.
5. What opportunities exist for new market entrants?
Limited, unless offering formulation innovations, improved stability, or combination products that address unmet needs.
References
[1] FDA National Drug Code Directory (2023).
[2] IQVIA Market Reports (2022).
[3] Red Book Online (2023).
[4] Pharmaceutical Commerce: Local Anesthetics Market Analysis (2022).
